Investors
We are committed to delivering our strategy and creating value for our shareholders.
Latest News
Latest Events
Verona Pharma and Nuance Pharma Announce $219 Million Strategic Collaboration to Develop and Commercialize Ensifentrine in Greater China
$40 million upfront including $25 million cash and $15 million in equity in Nuance Biotech (parent company). Up to $179 million in potential clinical, regulatory, and commercial milestone payments plus tiered double-digit royalties. Nuance Pharma is responsible for all costs related to development and commercialization of ensifentrine in China.
Verona Pharma to Present at Jefferies Virtual Healthcare Conference
LONDON and RALEIGH, N.C., May 25, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Chief Executive Officer and President, will present a company overview at the
Verona Pharma to Present Expanded Analysis of Phase 2b COPD Data with Ensifentrine at the American Thoracic Society 2021 International Conference
Posters highlight ensifentrine’s safety profile and its potential to improve lung function and quality of life irrespective of COPD severity LONDON and RALEIGH, N.C., May 04, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company
Discover More
Verona Pharma
Investor Information
© Verona Pharma plc 2021. All rights reserved